So, what's got Firefly Neuroscience Inc. (AIFF) shares buzzing on Friday? It's not just a little bump—the stock was up over 15%. The surge appears to be a continuation of momentum from a mid-week report detailing what can only be described as explosive growth in the company's core business: collecting and analyzing brain scan data.

Let's talk scale. Firefly reported that its commercial footprint—basically, the number of places using its tech—expanded by a factor of 20. It ended 2025 with partnerships at 99 commercial user sites. More importantly, the volume of electroencephalogram (EEG) and event-related potential (ERP) brain scans processed skyrocketed by 33 times. Those partners completed over 10,800 scans last year. In investor-speak, that translates to year-over-year increases of 1,880% in partner sites and 3,227% in clinical assessments. Those aren't typos.

All that scanning feeds Firefly's database, which it says now consists of over 191,000 EEG/ERP brain scans. The company is making a bold claim: this is the largest known standardized repository of this kind of brain data in the world. In the world of AI and machine learning, data is the new oil, and Firefly is claiming it just struck a gusher.

CEO Greg Lipschitz tied this data explosion directly to the company's research ambitions. "This growing foundation of clean data, combined with advanced NVIDIA Corp.'s (NVDA) L40S GPU acceleration, positions the company for breakthroughs in cognitive brain biomarker discovery," he said. In simpler terms, they're using a ton of brain scans and powerful NVIDIA chips to try and find digital fingerprints for cognitive conditions—think of it as a blood test, but for brain function.

Now, to the stock action. The share price movement has been... dramatic. The stock is currently trading 103.6% above its 20-day simple moving average and 18.1% above its 100-day average. That's textbook short-term strength. But the longer-term view provides crucial context: over the past 12 months, shares are still down about 63.4%, and they're closer to their 52-week low than their high. This recent rally is a big move off a low base.

The technical indicators are painting a somewhat conflicted picture, which is often the case after a sharp run-up. The Relative Strength Index (RSI) sits at 72.82, which is traditionally considered overbought territory. That often suggests a pullback could be due. On the other hand, the Moving Average Convergence Divergence (MACD) is at 0.0411, above its signal line, which indicates bullish momentum is still present. The takeaway? The momentum is mixed. The stock is strong right now, but the overbought reading is a yellow flag for traders.

For those watching the charts, key resistance is seen at the $2.00 level, while key support sits down at $1.00.

Putting a final number on it, Firefly Neuroscience shares were up 15.49% at $1.64 on Friday, according to market data.